Alzheimer's disease: critical notes on the history of a medical concept
- PMID: 23178566
- DOI: 10.1016/j.arcmed.2012.11.008
Alzheimer's disease: critical notes on the history of a medical concept
Abstract
It is generally accepted that Alois Alzheimer, the German neuropathologist and clinician, discovered the disease that carries his name, after the clinicopathological study of a 51-year-old woman named Auguste D. who presented a dementia syndrome. The pathological study of the brain revealed the presence of neurofibrillary tangles and senile plaques. Emil Kraepelin coined the eponym Alzheimer's disease in the 8th edition of his textbook Clinical Psychiatry. However, several critical aspects of this history have been pointed out by historians of psychiatry. This article provides a narrative of the best-known facts leading to the formation of the original concept but also presents an informed discussion of the main critical points: 1. The descriptions of senile plaques and neurofibrillary tangles in the context of dementia before Alzheimer's report. 2. The presence or absence of arteriosclerotic changes in the brain of Auguste D. 3. The presence of noncognitive symptoms in August D. 4. The influence of social, political and economic issues in the formation and selection of medical concepts.
Copyright © 2012 IMSS. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Oskar Fischer and the study of dementia.Brain. 2009 Apr;132(Pt 4):1102-11. doi: 10.1093/brain/awn256. Epub 2008 Oct 24. Brain. 2009. PMID: 18952676 Free PMC article.
-
[On the 100th anniversary of Alzheimer's disease].Ned Tijdschr Geneeskd. 2006 Dec 30;150(52):2880-2. Ned Tijdschr Geneeskd. 2006. PMID: 17319222 Dutch.
-
Reanalysis of the first case of Alzheimer's disease.Eur Arch Psychiatry Clin Neurosci. 1999;249 Suppl 3:10-3. doi: 10.1007/pl00014167. Eur Arch Psychiatry Clin Neurosci. 1999. PMID: 10654094
-
[Alzheimer and Alzheimer's disease: the present enlighted by the past. An historical approach].Psychol Neuropsychiatr Vieil. 2008 Jun;6(2):115-28. doi: 10.1684/pnv.2008.0122. Psychol Neuropsychiatr Vieil. 2008. PMID: 18556270 Review. French.
-
Neuropathology of Alzheimer's disease and related disorders.Neurol Clin. 2000 Nov;18(4):847-64. doi: 10.1016/s0733-8619(05)70229-2. Neurol Clin. 2000. PMID: 11072264 Review.
Cited by
-
Anti-neuroinflammatory Potential of Natural Products in Attenuation of Alzheimer's Disease.Front Pharmacol. 2018 May 29;9:548. doi: 10.3389/fphar.2018.00548. eCollection 2018. Front Pharmacol. 2018. PMID: 29896105 Free PMC article. Review.
-
Particulate Matter Exposure Exacerbates Amyloid-β Plaque Deposition and Gliosis in APP/PS1 Mice.J Alzheimers Dis. 2021;80(2):761-774. doi: 10.3233/JAD-200919. J Alzheimers Dis. 2021. PMID: 33554902 Free PMC article.
-
Role of berberine in Alzheimer's disease.Neuropsychiatr Dis Treat. 2016 Oct 3;12:2509-2520. doi: 10.2147/NDT.S114846. eCollection 2016. Neuropsychiatr Dis Treat. 2016. PMID: 27757035 Free PMC article. Review.
-
Role of PIM Kinase Inhibitor in the Treatment of Alzheimer's Disease.Mol Neurobiol. 2024 Dec;61(12):10941-10955. doi: 10.1007/s12035-024-04257-7. Epub 2024 May 30. Mol Neurobiol. 2024. PMID: 38816674 Review.
-
Early long-term administration of the CSF1R inhibitor PLX3397 ablates microglia and reduces accumulation of intraneuronal amyloid, neuritic plaque deposition and pre-fibrillar oligomers in 5XFAD mouse model of Alzheimer's disease.Mol Neurodegener. 2018 Mar 1;13(1):11. doi: 10.1186/s13024-018-0244-x. Mol Neurodegener. 2018. PMID: 29490706 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical